Insights Into Acute Lymphoblastic Leukemia (ALL)

Perspectives on current treatment practices regarding adult and AYA ALL, the role of MRD, and current treatment practices in relapsed/refractory disease

Southwest February 25, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas, MD Anderson Cancer Center, Houston, TX

Central March 11, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas, MD Anderson Cancer Center, Houston, TX

Southeast June 23, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas, MD Anderson Cancer Center, Houston, TX

Northeast August 25, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas, MD Anderson Cancer Center, Houston, TX

Midwest September 20, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas, MD Anderson Cancer Center, Houston, TX

Northwest November 8, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas, MD Anderson Cancer Center, Houston, TX

More Information

  • Virtual Series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual Series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual Series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More information

  • Virtual Series
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Virtual Series
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

More Information

  • Virtual Series
  • California, Nevada

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of acute lymphoblastic leukemia (ALL)
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: blinatumomab, ponatinib, inotuzumab ozogamicin, liposomal vincristine, and chimeric antigen receptor (CAR) T-cell therapy

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors will comprise 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.